Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
INFU · NYSE · United States · Surgical & Medical Instruments & Apparatus
In shortInfuSystem Holdings, Inc is profitable, generates cash and carries moderate debt, with revenue growing (+6.4% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 8.3% | 44/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 4.6% | 38/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 11.5% | 58/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 9.7% | 64/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.80× | 83/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.34× | 92/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.65× | 96/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 9.18× | 73/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.27 | 4/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 16.6% | 87/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 3.60× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 3.7% | 98/100 |
| Operating margin volatility | 2.6% | 85/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 9.3% | 68/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 102 | 110 | 126 | 135 | 143 |
| Cost of revenue | 44 | 49 | 63 | 64 | 63 |
| Gross profit | 59 | 61 | 63 | 70 | 80 |
| Operating income | 2.8 | 1.7 | 4.1 | 6.9 | 12 |
| Interest expense | 1.4 | 1.4 | 2.2 | 1.8 | 1.3 |
| Pre-tax income | 1.3 | 0.1 | 1.9 | 5.1 | 11 |
| Income tax | (0.2) | 0.1 | 1 | 2.7 | 4 |
| Net income | 1.4 | 0 | 0.9 | 2.3 | 6.6 |
| Diluted EPS | $0.06 | $0.00 | $0.04 | $0.11 | $0.31 |
| Diluted shares (millions) | 22 | 22 | 22 | 22 | 21 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
1.27 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 4, 2026